Bioactive materials · 2026
Dual metabolic checkpoint blockade via a 3D-Printed metalloplatform remodels the tumor ecosystem for systemic antitumor immunity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Meng Xiaoyan, Liu Zhonglong, Hao Yongqiang, Zhu Yingchun, Gu Jianfeng, Zhong Haozhang, He Yue, Fu Jingke
Аннотация
The immunosuppressive tumor microenvironment limits the efficacy of therapies that target metabolism. Here we show a strategy of dual metabolic regulation that simultaneously reprogramming glycolysis in cancer cells and fructose metabolism in tumor-associated macrophages, transforms the metabolic ecosystem from pro-tumor to antitumor, eliciting systemic immunity. Through pan-cancer single-cell analysis, we identified a metabolic division of labor: cancer cells exhibit hyperactive glycolysis, while immunosuppressive macrophages display elevated fructose metabolism. We uncovered that manganese ions (Mn2+) selectively suggest a potential inhibitory effect on glycolysis, induce pyroptosis, yet paradoxically upregulate fructose metabolism in M2-like macrophages, creating an exploitable vulnerability. To harness this dual activity, we engineered a 3D-printed nanoporous Cu-Mn alloy (CuMn) that provides sustained intratumoral release of Mn2+ and delivers a fructokinase inhibitor. In a bilateral breast carcinoma model, a single intratumoral implantation of this platform suppressed primary tumor growth and eradicated distant untreated lesions. Therapeutic efficacy was associated with macrophage reprogramming, which remodeled the immune microenvironment, alleviated T cell exhaustion, and inhibited distant tumor growth, suggesting potential systemic antitumor effects. Local delivery of the nano platform offers a strategy to overcome tumor immunosuppression and enhance cancer immunotherapy.